

Dr. Razan H. Haddad

Assistant Professor of Pharmaceutical Technology
Faculty of Pharmacy, Jadara University, Irbid, 21110, Jordan.

Email: razan.haddad@jadara.edu.jo
razanh@yaho.com



Personal Data

- **Name** : Razan Hani Haddad.
- **Date of birth** : 1/4/1991.
- **Nationality** : Jordanian.
- **Marital Status** : Married.
- **Gender** : Female.
- **Hobbies** : Reading, writing, walking, and cycling.

Education

- *Jordan University of Science & Technology (J.U.S.T), Irbid, Jordan.*
Ph.D. degree in Pharmaceutical Technology.
Faculty of Pharmacy, Class of 2022.
- *Jordan University of Science & Technology (J.U.S.T), Irbid, Jordan.*
Master's degree in Pharmaceutical Technology.
Faculty of Pharmacy, Class of 2017.
- *Jordan University of Science & Technology (J.U.S.T), Irbid, Jordan.*
Bachelor's degree of Science in Pharmacy.
Faculty of Pharmacy, Class of 2014.

Work Experience

- Assistant professor at Department of Pharmaceutical Sciences, Faculty of Pharmacy, Jadara University, from 1 Octobar 2022 until now.
- Assistant professor (part time) at Pharmaceutics and Pharmaceutical Technology Department, Faculty of Pharmacy, Alahliyya Amman University, from 1 March 2022 until 25 September 2022.

- Lecturer for pharmacy practice labs (the practice sections of the pharmaceuticals courses). at Pharmaceutical Technology Department, Faculty of Pharmacy, J.U.S.T from July 2017 to February 2022.
- Research assistant at Pharmaceutical Technology Department, Faculty of Pharmacy, J.U.S.T from February 2018 to February 2022.
- Teaching Assistant at Pharmaceutical Technology Department, Faculty of Pharmacy, J.U.S.T from February 2015 to June 2017.
- Trainee pharmacist at Lucy Chain Pharmacy for several months in 2014.

Research Experience

- Ph.D. thesis "Novel Modalities for The Nano Delivery of Hydrophobic Drugs and Site-Specific Targeting Delivery". **4 papers were published.**
- Nanocapsules in Drug Delivery. University of Santiago de Compostela, Santiago de Compostela, Spain. *(From 30 March to 2 July 2021).* **Published**
- Nanocrystals in Drug Delivery. Purdue University. West Lafayette, Indiana, USA. *(From 16 June to 2 August 2019).* **Published**
- Personalized Implants for Critical Size Bone Defects. Bonn University of Applied Science. Bonn, Germany. *(From 1 July to 20 September 2018).* **Published**
- Master thesis "Preparation and Characterization of an Oral Norethindrone Sustained Release Nanoparticles Formulation Based on Chitosan". **Published**
Developed and validated two HPLC-UV methods for norethindrone drug to measure its concentration in aqueous and (plasma and tissue) samples, respectively. **2 papers were published**
- Many projects and experience in pharmaceutical sciences and clinical pharmacy as shown from the publication record.

Personal Profile, Communication, and Technical Skills

- High communication skills and can easily deal with people.
- Working under pressure, managing time, and finishing tasks on time.
- Initiative, self-improvement skills, self-motivated, and self-confidence.
- Excellent leadership and administrative skills.
- Respect the work with others and estimate the spirit of teamwork.
- Excellent in solving problems and helping others to solve their problems.
- Arabic (Native language).

- English; reading, writing, speaking, listening (Excellent).

Conferences and Workshops

- The 13th International Colloids Conference. Sitges, Barcelona, Spain. (9th – 12th June 2024). *Participation and attendance.*
- The 5th International Conference of the Faculty of Pharmacy: "Multidisciplinary Pharmaceutical Research". Jordan University of Science and Technology. Irbid, Jordan. (7th – 8th June, 2023). *Attendance.*
- European Federation for Pharmaceutical Sciences (EUFEPS) Annual meeting 2021. Santiago de Compostela, Spain. (7th -9th June 2021). *Participation and attendance.*
- 79th FIP World Congress of Pharmacy and Pharmaceutical Science. Abu Dhabi, United Arab Emirates. (22 - 26 September 2019). *Participation and attendance.*
- The 14th International Conference of Jordan Cardiac Society in Collaboration with Jordan Cardiac Surgeons. Amman, Jordan. (22nd -24th September 2021). *Attendance.*
- "Graduate Students Research Conference" at Jordan University of Science and Technology, Irbid, Jordan, (18th April 2018). *Precipitation and attendance.*
- The 3rd International Conference of The Faculties of Pharmacy "Recent Trend in postgraduate Research" at the Applied Science University, Amman, Jordan. (15th-16th April 2017). *Precipitation and attendance.*
- JUST International Pharmacy Conference "Challenges Vs. Opportunities" at Jordan University of Science and Technology, Irbid, Jordan. (2nd-4th August 2017). *Precipitation and attendance.*
- New Trends in Pharmacy between Science and Industry Conference, at Faculty of Pharmacy, Yarmouk University, Irbid, Jordan. (22nd-23rd November 2017). *Attendance.*
- The IV Annual CiMUS Workshop, at The Center for Research in Molecular Medicine and Chronic Diseases (CiMUS), Santiago de Compostela, Spain. , (21st and 28th July 2021). *Precipitation and attendance.*
- Super Critical Fluids and their Application in Pharmaceutical Technology Workshop, The Arab Union of The Manufactures of Pharmaceuticals and Medical Applications, Amman, Jordan. (28th and 29th April 2019). *Attendance.*
- Manuscript Writing and Research Integrity Workshop, Faculty of Graduate Studies and Responsible Conduct of Research Program, Jordan University of Science and Technology, and the University of California in San Diego. Irbid, Jordan. (April. 2018). *Attendance.*

Awards

- Erasmus+ mobility program to travel to the University of Santiago de Compostela in Santiago de Compostela, Spain to participate in a workshop and a research project.
- 2019 FIP Congress Travel Scholarships to cover travel and accommodation costs to attend the FIP Congress of Pharmacy and Pharmaceutical Science in Abu Dhabi, United Arab Emirates.
- NRW scholarship to participate in a research project (Bone Tissue Engineering) at Bonn, Germany.
- Full scholarship from JUST University for a Ph.D. degree in Pharmaceutical Technology.
- Best poster award at the 3rd International Conference of The Faculties of Pharmacy at the Applied Science University, Amman, Jordan (15th-16th April 2017) which was about "Recent Trend in Postgraduate Research".

Publications

1. **Haddad R.** Artificial intelligence in the design and development of nanoparticle drug delivery systems: A systematic review. *Advances in Pharmacological and Pharmaceutical Sciences*. 2026;2026:5531134.
2. **Haddad R**, Al Taani B, Al Tarakji A, Alrabadi N. Kinetic and biocatalytic evaluation of dodecyl nicotinate hydrolysis in aqueous buffers and biological media. *Drug Development and Industrial Pharmacy*. 2026;52(3):602–616.
3. **Haddad R**, Gardouh AR. Development and evaluation of an orodispersible tablet formation for the delivery of a hydrophobic drug. *Advances in Pharmacological and Pharmaceutical Sciences*. 2024;2024(1):7914860.
4. Alshweiat A, Emran SO, Altaani B, **Haddad R**. Preparation and characterization of a low-molecular-weight chitosan nanoparticle-based ocular formulation for enhanced permeation of timolol maleate. *Current Drug Delivery*. 2026.
5. Khaled KH, Malkawi AS, Malkawi AS, **Haddad R**, Alrabadi N, Abu-Dahab R, Al-Bakri AG, Ovenseri AC. In vitro evaluation of novel nano-sized colloidal assemblies incorporating hydrophobic tobramycin ion pairs: Enhanced cellular uptake with preserved antimicrobial activity toward oral drug delivery. *Molecules*. 2026;31(12):2139.
6. Valverde-Fraga L, **Haddad R**, Alrabadi N, Sánchez S, Remuñán-López C, Csaba N. Design and in vitro assessment of chitosan nanocapsules for the pulmonary delivery of rifabutin. *European Journal of Pharmaceutical Sciences*. 2023:106484.
7. **Haddad R**, Alrabadi N, Altaani B, Masadeh M, Li T. Hydroxypropyl beta cyclodextrin as a potential surface modifier for paclitaxel nanocrystals. *AAPS PharmSciTech*. 2022;23(6):1–11.
8. **Haddad R**, Alrabadi N, Altaani B, Li T. Paclitaxel drug delivery systems: Focus on nanocrystals' surface modifications. *Polymers*. 2022;14(4):658.
9. Altaani B, **Haddad R**, Kossa M, Al-Balas Q, Alrabadi N. Synthesis of sorbitan esters of jojoba oil fatty acids as surfactants: Physicochemical characterization and obtaining solid dispersion of ibuprofen to enhance dissolution. *Farmacia*. 2024;72(2).

10. Altaani B, **Haddad R**, Al-Tarakji A, Alrabadi N. Hydrolysis kinetics of the prodrug myristyl nicotinate. *Pharmaceutical Development and Technology*. 2022.
11. Malkawi A, Alrabadi N, **Haddad R**, Malkawi A, Khaled K, Ovenseri AC. Development of self-emulsifying drug delivery systems (SEDDSs) displaying enhanced permeation of the intestinal mucus following sustained release of prototype thiol-based mucolytic agent load. *Molecules*. 2022;27(14):4611.
12. Alrabadi N, Hamdan M, **Haddad R**, Sabi SH, Masadeh MM, Alzoubi KH, Al-Batayneh KM. Development and evaluation of the efficacy and toxicity of a new hybrid antimicrobial peptide MY8. *Current Pharmaceutical Design*. 2023;29(43):3488–3496.
13. Masadeh MM, Ayyad A, **Haddad R**, Alsagar M, Alzoubi K, Alrabadi N. Functional and toxicological evaluation of the MAA-41: A novel rationally designed antimicrobial peptide using hybridization and modification methods from LL-37 and BMAP-28. *Current Pharmaceutical Design*. 2022.
14. Malkawi AS, **Haddad R**, Malkawi A, Alrabadi N. Development of fluorescently labeled self-emulsifying drug delivery systems (SEDDS) for in vitro sustained release, sustained cellular uptake, and prolonged stability. *Pharmaceutical Nanotechnology*. 2022. doi:10.2174/2211738510666220314103400.
15. Masadeh MM, Laila SA, **Haddad R**, Alzoubi K, Alhaijaa AA, Alrabadi N. The antimicrobial effect against multi-drug resistant bacteria of the SK4 peptide: A novel hybrid peptide of Cecropin-A and BMAP-27. *Current Pharmaceutical Biotechnology*. 2023;24(8):1070–1078.
16. Witzler M, Vermeeren S, Kolevatorov R, **Haddad R**, Gericke M, Heinze T, Schulze M. Evaluating release kinetics from alginate beads coated with polyelectrolyte layers for sustained drug delivery. *ACS Applied Bio Materials*. 2021;4(9):6719–6731.
17. Al-Tanni BM, Alkhamis KA, Abu Baker SA, **Haddad R**. The relationship between the Hammett acidity and the decomposition of cefotaxime sodium in the solid-state. *Drug Development and Industrial Pharmacy*. 2020;46(10):1632–1638.
18. Altaani BM, Al-Nimry SS, **Haddad RH**, Abu-Dahab R. Preparation and characterization of an oral norethindrone sustained release/controlled release nanoparticles formulation based on chitosan. *AAPS PharmSciTech*. 2019;20(2):54.
19. Al-Nimry SS, Altaani BM, **Haddad RH**. RP-HPLC method for determination of norethindrone in dissolution media and application to study release from a controlled release nanoparticulate liquid medicated formulation. *Journal of Applied Pharmaceutical Science*. 2019;9(2):79–86.
20. Almaaytah A, Mashagbeh H, **Haddad R**. Current status of biosimilar regulations in the MENA region. *International Journal of Research in Pharmaceutical Sciences*. 2020;11(3):3443–3449.
21. Al-Nimry SS, Altaani BM, **Haddad RH**. RP-HPLC method for estimating norethindrone in plasma and tissues following administration of a controlled release nanoparticulate liquid formulation. *Indian Journal of Pharmaceutical Sciences*. 2020;82(4):593–600.
22. Alrabadi N, Al-Nusair M, **Haddad R**, Alwaqfi B, Shalabi M, El-Zubi FK, Jarrah M, Harati R, Alzoubi KH, Hammoudeh A. Characteristics and outcomes of Middle Eastern patients with atrial fibrillation and history of prior stroke or systemic embolism. *Postgraduate Medicine*. 2025;137(6):537–542.
23. Alrabadi N, Obeidat H, **Haddad R**, Alzoubi O, Al-Rabadi D, Jaradat S, El-Zubi MK, Harati R, Alzoubi KH, Al-Faouri I. One-year seropositivity after COVID-19 infection: A study from a developing country. *Medicine*. 2026;105(10).
24. Alrabadi N, Al-Nusair M, **Haddad R**, Alburie L, Mhaidat N, Jarrah MI, Hammoudeh A. Clinical predictors of warfarin response among patients with atrial fibrillation: Evidence from the Middle Eastern JoFib study. *Current Vascular Pharmacology*. 2025.

25. Haddad RH, Price MM, **Haddad R**, Abuejheisheh AJ, Abuhashish YH, Hamdan-Mansour AM. Improving subjective well-being through EMDR therapy among PTSD patients in Jordan: A quasi-experimental study. *Chronic Stress*. 2025;9:24705470251352627.
26. Alzoubi KH, Khabour OF, Al-Sawalha N, Al Momany EM, Jarab A, **Haddad R**, Alrabadi N, Alqudah MA, Al-Zoubi TK, Eissenberg T. Vitamin C protects from impairment of memory induced by e-cigarette aerosol exposure. *Current Neuropsychopharmacology*. 2025.
27. Aljanabi MA, Alrabadi N, Mahmoud SH, **Haddad R**, Alzoubi KH. Sildenafil effect on atrial natriuretic peptide level in pulmonary hypertensive rats. *Cardiovascular & Hematological Agents in Medicinal Chemistry*. 2024.
28. Alrabadi N, Obeidat H, **Haddad R**, Alyassin N, Alzoubi KH, Obeidat O, Shteiwi SM, Al-Rabadi D, Al-Faouri I. The value of using COVID-19 antibody tests as a potential approach to prioritize vaccination delivery. *PLOS ONE*. 2024;19(10).
29. Al-Nusair M, Alrabadi N, **Haddad R**, Njem S, Aljarrah MI, Hammoudeh A. Residual risk of thromboembolic events despite anticoagulation in Middle Eastern patients with atrial fibrillation: The JoFib study. *Journal of Stroke and Cerebrovascular Diseases*. 2024;33(8):107785.
30. Alrabadi N, Al-Nusair M, **Haddad R**, Alghizzawi BS, Al-Nusair N, Alhaj Mohammad S, Shteiwi SM, El-Zubi MK, Marie Z, Alnsour A, Jarrah M. Sex differences in clinical features, utilization of oral anticoagulant agents, and 1-year outcome in Middle Eastern patients with atrial fibrillation. *Current Medical Research and Opinion*. 2024;40(5):745–752.
31. Alrabadi N, Al-Faouri I, **Haddad R**, Al-Rabadi D, Alnsour A, Alzoubi O, Obeidat O, Alzoubi KH. The risk of COVID-19 infection among nurses working with COVID-19 patients. *Medicine*. 2023;102(49).
32. Alrabadi N, **Haddad R**, Al-Faouri I, Obeidat N, Al-Ghazo M, El-Salem K, Elnasser Z, Mhaidat N. Positive COVID-19-PCR patients as negative controls for COVID-19 antibody tests. *Annals of Medicine and Surgery*. 2021;102320.
33. Alrabadi N, **Haddad R**, Albustami I, Al-Faouri I, Obeidat N, Al-Ghazo M, Al-Rabadi D, Khassawneh A. The lockdown may contribute to the COVID-19 cases in developing countries: Different perspectives on the curfew act, a report from Jordan. *Annals of Medicine and Surgery*. 2021;61:41–43.
34. Al-Faouri I, **Haddad R**, Hayagneh W, Obeidat N, Al-Ghazo M, Alrabadi N. Management of COVID-19 crisis: Focus on immunization, vaccination, and safe re-locating of health care providers. *Annals of Medicine and Surgery*. 2020;60:555.
35. Haddad RH, Al-Bashaireh AM, **Haddad R**, Abuejheisheh AJ. Predictors of war-related stress and resilience among Palestinian nursing students experiencing chronic war exposure. *Chronic Stress*. 2026;10:24705470261434080.
36. Abdelfatah AM, Sayed FM, Ali FK, Haddad RH, **Haddad R**, Tohol WJ, Osman NE, Abuejheisheh AJ. Changes in self-concept and healthy behaviors following an audio instructional program on puberty among teenage girls with visual impairment: A quasi-experimental study. *BMC Public Health*. 2026.
37. Haddad RH, Alhusamiah BK, **Haddad R**, Hamdan-Mansour AM, Abuhashish YH, Alshraideh JA. The effectiveness of using eye movement desensitization and reprocessing therapy on reducing the severity of symptoms among individuals diagnosed with post-traumatic stress disorder: A systematic review of literature to highlight the standardized therapy-based interventional protocol. *Mental Health and Social Inclusion*. 2024.
38. Haddad RH, Alhusamiah BK, **Haddad R**, Aldaieflih MT, Yaseen K, Abuhashish YH, Hamdan-Mansour AM, Alshraideh JA. The effectiveness of using cognitive behavioral therapy and internet-based cognitive behavioral therapy interventions on relapse prevention and severity of symptoms among patients diagnosed with major depressive disorder: A systematic review of randomized controlled trials. *Mental Health and Social Inclusion*. 2024.

39. Alrabadi N, Al-Nusair M, **Haddad R**, Alburie L, Mhaidat N, Aljarrah M, Hamoudeh A. Cardiovascular medications used for comorbid diseases in patients with atrial fibrillation: The JoFib study. *European Journal of Clinical Pharmacology*. 2024;1–8.
40. Alrabadi N, Aljarrah Q, Alzoubi O, Al-Jarrah H, Elayyan Y, Alnabulsi Z, Husein A, Alzoubi KH, Bakkar S, Aljanabi M, Zihlif M, **Haddad R**. Clinical recurrence and antiplatelet drug resistance among patients with lower limb ischemia. *Medicine*. 2024;103(2).
41. Alrabadi NN, Abushukair HM, Ababneh OE, Syaj SS, Al-Horani SS, Qarqash AA, Darabseh OA, Al-Sous MM, Al-Aomar SR, Ahmed YB, **Haddad R**. Efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: A systematic review and meta-analysis. *Clinical and Translational Oncology*. 2021:1–20.
42. Alrabadi N, **Haddad R**, Alomari AK. Detection of gene mutations in liquid biopsy of melanoma patients: Overview and future perspectives. *Current Treatment Options in Oncology*. 2020;21(3):19.
43. Alrabadi N, Albustami IS, Abuhayyeh HA, El-Muwalla KM, Alawneh RJ, Al-Eitan LN, Alzoubi KH, Masadeh M, Khabour OF, **Haddad R**. Clavulanic acid in the scope of *Helicobacter pylori* treatment: A literature review and beyond. *Current Clinical Pharmacology*. 2020.
44. Alrabadi N, **Haddad R**, Haddad R, Shawagfeh S, Mukatash T, Al-Rabadi D, Abuhammad S. Medication errors among registered nurses in Jordan. *Journal of Pharmaceutical Health Services Research*. 2020;11(3):237–243.
45. Al-Rabadi N, **Haddad R**, Al-Hijazeen M, Massoh M, Alqudah J, Jiries A, Alu'datt M, Al-Dalain S, Al-Dmour R, AlNasir F, Mayyas A, Al-Rabadi G. Effect of garlic powder supplementation level at different growth stages on broiler performance. *Bulletin of Environment, Pharmacology and Life Sciences*. 2020;9(11):67–76.
46. Alrabadi N, Shawagfeh S, **Haddad R**, Mukatash T, Abuhammad S, Al-Rabadi D, Abu Farha R, Alrabadi S, Al-Faouri I. Medication errors: A focus on nursing practice. *Journal of Pharmaceutical Health Services Research*. 2020.
47. Al-Rabadi GJ, Hijazeen MA, Al-Rawashdeh MS, Al-Dalain SA, Tamer E, Al-Nasir F, **Haddad R**, Alrabadi N. Assessment of heavy metals in milk and dairy cattle feed in Syria: Correlation analysis. *Bulletin of Environment, Pharmacology and Life Sciences*. 2019;1(9):43–47.

References

1) Dr. Bashar Al-Taani

Professor at Jordan University of Science and Technology, Faculty of Pharmacy, Department of Pharmaceutical Technology.

Email: altaani@just.edu.jo

2) Dr. Nasr Alrabadi

Professor at Jordan University of Science and Technology, Faculty of Medicine, Department of Pharmacology.

Email: nnalrabadi@just.edu.jo